Loading clinical trials...
Loading clinical trials...
Phase II Study of High-dose Rate (HDR) Monotherapy for the Treatment of Low and Intermediate Risk Prostate Cancer
The purpose of this study is to determine the clinical efficacy and toxicity of High-dose rate (HDR) brachytherapy as monotherapy for the treatment of low risk and intermediate risk prostate cancer.
Age
18 - No limit years
Sex
MALE
Healthy Volunteers
No
CSSS de Gatineau
Gatineau, Quebec, Canada
Start Date
April 1, 2014
Primary Completion Date
March 1, 2026
Completion Date
March 1, 2026
Last Updated
February 21, 2024
50
ESTIMATED participants
HDR brachytherapy monotherapy
RADIATION
Lead Sponsor
CSSS de Gatineau
NCT06842498
NCT04550494
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT05691465